Valneva SE, a company specialized in vaccines, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. The company is headquartered in Saint-Herblain, France.
| Revenue (TTM) | $156.33M |
| Gross Profit (TTM) | $-39.51M |
| EBITDA | $-81.88M |
| Operating Margin | -76.70% |
| Return on Equity | -109.60% |
| Return on Assets | -14.50% |
| Revenue/Share (TTM) | $1.79 |
| Book Value | $0.99 |
| Price-to-Book | 5.68 |
| Price-to-Sales (TTM) | 3.21 |
| EV/Revenue | 3.353 |
| EV/EBITDA | 26.94 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -37.20% |
| Shares Outstanding | $94.82M |
| Float | $73.69M |
| % Insiders | 0.00% |
| % Institutions | 3.62% |